We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Subscribe To Our Newsletter & Stay Updated